



## FOR IMMEDIATE RELEASE

Contact:  
Shawn Farley  
Public Relations Manager  
(703) 648-8936  
[sfarley@acr.org](mailto:sfarley@acr.org)

### **ACR Image Metrix™ Publicizes Positron Emission Tomography (PET) Services**

(June 16, 2009; Philadelphia, PA) – [American College of Radiology \(ACR\) Image Metrix™](#), a leader in imaging trial design, techniques, data extraction, management and analysis, possesses unparalleled experience and infrastructure to assist pharmaceutical and biotech companies in implementing cutting-edge positron emission tomography (PET) services into their clinical research programs.

PET and PET/CT have increasingly become important tools in the process of drug development, especially for novel anticancer drugs. ACR Image Metrix, housed in the American College of Radiology Clinical Research Center, draws on the same infrastructure which enables the American College of Radiology® (ACR®) and [American College of Radiology Imaging Network™](#) (ACRIN™) to manage the National Oncologic PET Registry and conduct large scale PET trials, including [ACRIN 6668](#) and [ACRIN 6678](#). ACR Image Metrix is putting the knowledge gleaned from these enterprises to work for its clients today.

PET is widely recognized as the vanguard of molecular imaging. Its high photon detection efficiency and spatial resolution, high quantitative accuracy, and the fact that it can be used with a wide variety of radiopharmaceuticals to interrogate regional physiology or pathophysiology can give it certain advantages over conventional radionuclide imaging.

Assessment of tumor metabolism with the glucose analogue 18F-fluorodeoxyglucose (FDG) FDG is the most widely used PET imaging method in oncology, exploiting the fact that most malignant tumors exhibit an increased rate of glucose utilization. At the simplest level, the improved accuracy of cancer staging provided by FDG-PET is now routinely used in many clinical trials to ensure that patients are properly staged before registration. FDG-PET is also used in the early clinical phases of drug development as a

biomarker of response to therapy. Beyond FDG-PET, novel radionuclides, like 18FLT and 18FMISO, enable clinical investigation of a range of other important biological activities.

“Important aspects of tumor biology, which are relevant to understanding the mechanisms of drug action, can be evaluated by PET and embedded as correlative studies in early-phase clinical trials,” stated Bruce Hillman, M.D., ACR Image Metrix, Chief Scientific Officer. “PET also has importance in drug development fields other than oncology, such as receptor occupancy and pharmacokinetic studies of various neuroreceptor ligands and the increasing use of amyloidbinding PET tracers to assess the effectiveness of novel treatments for Alzheimer’s disease.”

“ACR Image Metrix is supported by a state-of-the-art [PET core laboratory](#) throughout the development and implementation of clinical trials that incorporate PET imaging. The core lab has been involved in establishing quantitative endpoints for imaging trials and standardized procedures for imaging acquisition and analysis,” said Barry Siegel, M.D., Chair of the PET Core Laboratory. “The core lab is a tremendous resource for organizations in need of high-quality PET research.”

“ACR Image Metrix has access to resources that few, if any, other contract research organizations have in regard to PET and other imaging procedures. ACR Image Metrix is a leader in the use of cutting-edge imaging techniques in drug discovery and development, and stands ready to provide expertise from leading PET experts and mobilize considerable resources on behalf of our clients,” said ACR Image Metrix General Manager, Michael Morales.

ACR Image Metrix will be exhibiting at the Drug Information Association (DIA) 45<sup>th</sup> Annual Meeting in San Diego, California, June 22-24. Bruce Hillman, M.D. and Mehdi Adineh, Ph.D. will be at the ACR Image Metrix booth #212. We invite you to unlock the true potential of imaging and visit with our imaging experts.

***About ACR Image Metrix***

ACR Image Metrix, located in the American College of Radiology Clinical Research Center, applies imaging techniques as a predictive and prognostic biomarker improving the efficiency for drug and medical device development programs. The world-class team of physicians and scientists at ACR Image Metrix work with pharmaceutical, biotech and medical device companies to increase the efficiency of drug and medical device development programs by integrating the appropriate imaging modalities. ACR Image Metrix has years of experience and proven expertise in employing state-of-the-art technologies to provide a complete line of imaging services.

###